ArticleBMC gastroenterology2023

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.

Michael Trauner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.